Samsung Biologics has chosen Rapid Micro Biosystems’ Growth Direct® platform to automate its microbial quality control processes. The Growth Direct® platform is a fully automated, non-destructive growth-based platform for microbiology quality control testing, offering faster time to results, improved data integrity, and enhanced accuracy. Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), selected the platform to deliver increased efficiency, more robust data integrity, and scalable quality control operations. The Growth Direct® platform improves operational efficiency and data integrity in the quality control microbiology lab. Rapid Micro Biosystems is an innovative life sciences technology company that provides mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables.